Comparative Efficacy and Safety of Oral P2Y₁₂ Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials.

ABSTRACT:

Background

New randomized, controlled trials have become available on oral P2Y₁₂ inhibitors in acute coronary syndrome. We aimed to evaluate current evidence comparing the efficacy and safety profile of prasugrel, ticagrelor, and clopidogrel in acute coronary syndrome by a meta-analysis of randomized controlled trials.

Methods

We performed a network meta-analysis and direct pairwise comparison analysis of efficacy and safety outcomes from 12 randomized controlled trials including a total of 52 816 patients with acute coronary syndrome.

Results

In comparison with clopidogrel, ticagrelor significantly reduced cardiovascular mortality (hazard ratio [HR], 0.82 [95% CI, 0.72-0.92]) and all-cause mortality (HR, 0.83 [95% CI, 0.75-0.92]), whereas there was no stat

SUBMITTER: Navarese EP 

PROVIDER: S-EPMC7489363 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature